LOGIN  |  REGISTER
Viking Therapeutics

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 131.50
-1.55 -1.16
6.12M
1.73B
US$ 227.500B
US$ 543.00
-4.07 -0.74
1.08M
356.18M
US$ 193.410B
US$ 104.50
-0.14 -0.13
5.42M
1.47B
US$ 153.620B
US$ 400.48
2.20 0.55
2.81M
382.50M
US$ 153.180B
US$ 378.28
-1.47 -0.39
1.02M
381.22M
US$ 144.210B
US$ 187.48
0.67 0.36
2.78M
722.28M
US$ 135.410B
US$ 80.91
-3.50 -4.15
13.83M
1.28B
US$ 103.560B
US$ 710.64
-8.09 -1.13
577,846
126.94M
US$ 90.210B
US$ 172.31
-0.83 -0.48
2.04M
290.01M
US$ 49.970B
US$ 74.79
-1.31 -1.72
4.08M
589.80M
US$ 44.110B
US$ 86.14
-1.40 -1.60
2.48M
494.60M
US$ 42.600B
US$ 504.83
3.96 0.79
532,651
81.88M
US$ 41.340B
US$ 152.49
-0.82 -0.53
1.08M
242.01M
US$ 36.900B
US$ 245.49
-0.29 -0.12
624,706
146.80M
US$ 36.040B
US$ 84.83
-0.06 -0.07
1.63M
390.60M
US$ 33.130B
US$ 109.68
-26.42 -19.41
1.71M
285.60M
US$ 31.320B
US$ 138.04
0.75 0.55
2.56M
181.50M
US$ 25.050B
US$ 243.80
-2.53 -1.03
517,224
98.71M
US$ 24.070B
US$ 1.00
2.74 0.24
174,385
21.10M
US$ 23.970B
US$ 321.00
-3.50 -1.08
980,534
70.14M
US$ 22.510B
US$ 348.46
1.10 0.32
388,213
59.38M
US$ 20.690B
US$ 241.89
0.55 0.23
510,299
83.64M
US$ 20.230B
US$ 152.48
1.39 0.92
1.01M
132.02M
US$ 20.130B
US$ 169.62
-0.86 -0.50
999,522
111.62M
US$ 18.930B
US$ 91.67
-1.07 -1.15
1.94M
199.07M
US$ 18.250B
US$ 79.30
-0.07 -0.09
1.98M
199.58M
US$ 15.830B
US$ 30.27
-0.16 -0.53
2.76M
510.59M
US$ 15.460B
US$ 208.49
-0.46 -0.22
433,598
72.42M
US$ 15.100B
US$ 80.54
1.17 1.47
1.95M
158.60M
US$ 12.770B
US$ 28.40
-0.32 -1.11
657,104
435.99M
US$ 12.380B
US$ 54.48
-0.34 -0.62
1.62M
225.72M
US$ 12.300B
US$ 90.48
0.65 0.72
1.15M
121.70M
US$ 11.010B
US$ 126.99
0.37 0.29
817,339
82.56M
US$ 10.480B
US$ 56.48
-0.41 -0.72
2.64M
185.08M
US$ 10.450B
US$ 266.75
-3.64 -1.35
293,539
38.38M
US$ 10.240B
US$ 42.32
0.00 0.00
1.26M
222.26M
US$ 9.410B
US$ 293.03
-2.74 -0.93
377,378
31.08M
US$ 9.110B
US$ 59.36
1.22 2.10
12.27M
152.40M
US$ 9.050B
US$ 149.91
0.52 0.35
491,752
53.54M
US$ 8.030B
US$ 135.60
0.62 0.46
1.29M
51.14M
US$ 6.930B
US$ 120.45
0.24 0.20
535,093
56.03M
US$ 6.750B
US$ 58.60
-0.68 -1.15
1.55M
113.74M
US$ 6.670B
US$ 120.94
-1.03 -0.84
415,379
46.44M
US$ 5.620B
US$ 95.11
-1.38 -1.43
534,212
58.28M
US$ 5.540B
US$ 36.34
-0.11 -0.30
2.30M
151.60M
US$ 5.510B
US$ 97.19
2.37 2.50
857,659
55.14M
US$ 5.360B
US$ 227.14
-0.84 -0.37
358,864
22.92M
US$ 5.210B
US$ 74.75
-0.38 -0.51
1.20M
69.53M
US$ 5.200B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 37.05
-0.04 -0.11
1.46M
123.56M
US$ 4.580B
US$ 142.44
2.57 1.84
381,300
31.30M
US$ 4.460B
US$ 145.95
-0.14 -0.10
503,170
29.97M
US$ 4.370B
US$ 85.01
0.59 0.70
367,751
49.41M
US$ 4.200B
US$ 56.77
-1.29 -2.22
481,900
74.03M
US$ 4.200B
US$ 123.34
2.03 1.67
743,425
33.56M
US$ 4.140B
US$ 118.16
-0.72 -0.61
512,443
33.54M
US$ 3.960B
US$ 11.25
0.06 0.54
528,873
352.16M
US$ 3.960B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 12.26
-0.08 -0.65
700,290
283.24M
US$ 3.470B
US$ 66.16
-0.76 -1.14
379,428
50.22M
US$ 3.320B
US$ 130.73
-0.02 -0.02
212,277
24.48M
US$ 3.200B
US$ 57.72
1.08 1.91
597,356
54.11M
US$ 3.120B
US$ 43.18
-0.48 -1.10
548,293
54.30M
US$ 2.340B
US$ 20.17
0.13 0.65
3.57M
101.66M
US$ 2.050B
US$ 30.18
0.60 2.03
1.53M
67.26M
US$ 2.030B
US$ 18.11
0.36 2.03
864,569
108.20M
US$ 1.960B
US$ 79.12
-2.38 -2.92
218,215
22.48M
US$ 1.780B
US$ 12.48
-0.18 -1.42
881,043
141.77M
US$ 1.770B
US$ 56.06
-1.35 -2.35
250,322
30.89M
US$ 1.730B
US$ 28.16
-0.31 -1.09
1.30M
59.58M
US$ 1.680B
US$ 32.81
-0.45 -1.35
470,791
48.75M
US$ 1.600B
US$ 20.64
-1.01 -4.67
1.48M
65.68M
US$ 1.360B
US$ 6.19
-0.03 -0.48
3.18M
216.94M
US$ 1.340B
US$ 38.77
1.31 3.50
1.57M
33.60M
US$ 1.300B
US$ 28.03
0.55 2.00
1.19M
45.69M
US$ 1.280B
US$ 8.94
-0.12 -1.32
783,545
134.56M
US$ 1.200B
US$ 28.46
-0.09 -0.32
355,092
41.92M
US$ 1.190B
US$ 22.59
-1.40 -5.84
220,651
49.60M
US$ 1.120B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 14.33
0.12 0.84
861,263
76.25M
US$ 1.090B
US$ 36.85
0.97 2.70
246,388
28.76M
US$ 1.060B
US$ 16.86
-0.44 -2.54
171,111
61.52M
US$ 1.040B
US$ 22.10
0.01 0.05
246,418
46.39M
US$ 1.030B
US$ 6.72
-0.18 -2.61
419,766
146.95M
US$ 987.500M
US$ 18.47
-0.13 -0.70
170,070
52.94M
US$ 977.800M
US$ 12.66
-0.03 -0.24
1.02M
77.16M
US$ 976.850M
US$ 7.28
-0.12 -1.62
2.53M
128.36M
US$ 934.460M
US$ 18.77
0.32 1.73
498,858
49.28M
US$ 924.990M
US$ 17.11
0.06 0.35
1.08M
53.63M
US$ 917.610M
US$ 1.27
-0.03 -2.31
2.43M
672.80M
US$ 854.460M
US$ 18.42
-0.70 -3.66
280,981
41.94M
US$ 772.530M
US$ 52.28
-0.93 -1.75
20,264
12.67M
US$ 662.390M
US$ 15.89
-0.12 -0.75
728,722
40.30M
US$ 640.370M
US$ 20.52
0.24 1.18
277,491
30.59M
US$ 627.710M
US$ 17.26
-0.29 -1.65
245,448
35.82M
US$ 618.250M
US$ 16.15
-1.09 -6.32
842,962
36.20M
US$ 584.630M
US$ 12.48
-0.22 -1.73
377,394
45.96M
US$ 573.580M
US$ 17.87
-0.26 -1.43
332,564
29.85M
US$ 533.420M
US$ 6.88
0.01 0.15
1.29M
77.11M
US$ 530.520M
US$ 3.77
0.15 4.14
105,445
139.82M
US$ 527.120M
US$ 21.15
-0.70 -3.20
95,756
24.22M
US$ 512.250M
US$ 10.94
-0.46 -4.04
687,934
44.01M
US$ 481.470M
US$ 15.89
-0.13 -0.81
287,622
28.01M
US$ 445.080M
US$ 11.23
-0.28 -2.43
636,224
38.21M
US$ 429.100M
US$ 6.51
0.01 0.15
263,778
65.37M
US$ 425.560M
US$ 29.16
0.06 0.21
137,574
14.29M
US$ 416.700M
US$ 44.93
0.04 0.09
2.37M
9.27M
US$ 416.500M
US$ 2.14
-0.02 -0.93
1.79M
186.64M
US$ 399.410M
US$ 4.18
-0.16 -3.69
832,892
92.44M
US$ 386.400M
US$ 9.41
-0.16 -1.67
395,351
40.47M
US$ 380.820M
US$ 6.10
-0.19 -3.02
310,456
62.30M
US$ 380.030M
US$ 3.93
-0.14 -3.44
2.17M
91.04M
US$ 357.790M
US$ 0.95
-0.09 -8.27
2.09M
372.26M
US$ 355.140M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 13.79
0.40 2.99
80,220
23.48M
US$ 323.790M
US$ 7.73
0.09 1.18
292,689
41.23M
US$ 318.710M
US$ 2.45
-0.03 -1.21
1.37M
128.81M
US$ 315.580M
US$ 0.53
0.03 5.00
6.23M
595.33M
US$ 312.550M
US$ 8.32
0.27 3.35
195,008
37.43M
US$ 311.420M
US$ 5.24
0.00 0.00
1.79M
58.52M
US$ 306.640M
US$ 0.95
-0.03 -3.18
12.07M
294.32M
US$ 279.600M
US$ 30.65
-0.37 -1.19
15,358
8.74M
US$ 267.880M
US$ 6.52
-0.15 -2.25
111,571
38.94M
US$ 253.890M
US$ 4.85
0.04 0.83
439,908
49.57M
US$ 240.410M
US$ 1.73
0.26 17.29
25.60M
138.40M
US$ 239.430M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 2.25
0.05 2.27
1.52M
105.48M
US$ 237.330M
US$ 9.81
-0.04 -0.41
204,918
24.00M
US$ 235.440M
C$ 0.83
-0.01 -1.19
75,500
282.82M
C$ 234.740M
US$ 8.35
-0.17 -2.00
103,831
27.60M
US$ 230.460M
US$ 3.99
-0.02 -0.50
567,994
55.65M
US$ 222.040M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 10.43
0.03 0.29
36,897
18.82M
US$ 196.290M
US$ 2.57
0.02 0.79
635,242
74.59M
US$ 191.320M
US$ 53.66
0.34 0.64
10,461
3.39M
US$ 181.910M
US$ 20.35
-0.52 -2.49
84,693
8.46M
US$ 172.160M
US$ 2.02
-0.02 -0.98
127,524
84.73M
US$ 171.150M
US$ 2.51
0.05 2.03
684,137
67.59M
US$ 169.650M
US$ 6.40
-0.12 -1.84
224,575
26.22M
US$ 167.810M
US$ 3.28
0.04 1.23
82,840
50.40M
US$ 165.310M
US$ 4.74
0.09 1.94
375,793
34.82M
US$ 165.050M
US$ 5.35
-0.09 -1.65
40,294
30.49M
US$ 163.120M
US$ 13.98
0.00 0.00
145,517
11.61M
US$ 162.310M
US$ 6.65
0.39 6.23
284,059
24.26M
US$ 161.330M
US$ 6.75
0.79 13.26
595,619
23.82M
US$ 160.780M
US$ 1.58
-0.04 -2.47
375,268
100.56M
US$ 158.880M
US$ 5.13
0.00 0.00
91,899
30.03M
US$ 154.050M
US$ 45.62
1.22 2.75
34,474
3.26M
US$ 148.720M
US$ 2.72
-0.08 -2.86
124,030
45.84M
US$ 124.680M
US$ 0.79
-0.0052 -0.65
42,062
156.55M
US$ 124.300M
US$ 5.80
-0.25 -4.13
429,026
21.26M
US$ 123.310M
US$ 3.12
-0.02 -0.64
226,796
39.49M
US$ 123.210M
US$ 3.15
-0.01 -0.32
76,167
37.72M
US$ 118.820M
US$ 10.99
2.90 35.85
122,294
10.64M
US$ 116.930M
US$ 3.23
-0.33 -9.27
102,857
35.94M
US$ 116.090M
US$ 3.21
-0.01 -0.31
449,824
33.70M
US$ 108.180M
US$ 6.03
0.26 4.51
137,483
17.64M
US$ 106.370M
US$ 2.06
-0.03 -1.44
85,465
49.50M
US$ 101.970M
US$ 0.73
0.04 5.20
65,296
139.01M
US$ 100.920M
US$ 2.62
-0.18 -6.43
76,482
34.31M
US$ 89.890M
US$ 13.96
0.26 1.90
24,231
6.27M
US$ 87.530M
US$ 5.05
0.06 1.10
13,018
16.04M
US$ 80.920M
US$ 1.33
0.00 0.00
722,096
59.34M
US$ 78.920M
US$ 4.68
-0.03 -0.64
58,609
16.39M
US$ 76.710M
US$ 1.75
-0.20 -10.26
1.16M
43.09M
US$ 75.410M
US$ 0.97
-0.03 -2.70
6,936
77.89M
US$ 75.240M
US$ 2.30
0.03 1.32
131,969
31.85M
US$ 73.260M
US$ 2.56
0.02 0.79
1.03M
28.03M
US$ 71.760M
US$ 2.11
0.09 4.46
421,445
32.02M
US$ 67.560M
US$ 1.14
0.01 0.88
28,530
59.23M
US$ 67.520M
US$ 1.80
0.06 3.45
45,422
37.10M
US$ 66.780M
US$ 1.30
0.00 0.00
989,871
49.57M
US$ 64.440M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 1.66
0.18 12.16
135,778
37.64M
US$ 62.480M
US$ 1.88
-0.04 -2.08
259,059
32.80M
US$ 61.660M
US$ 3.35
-0.16 -4.56
165,177
18.34M
US$ 61.440M
US$ 2.09
0.06 2.96
14,228
29.25M
US$ 61.130M
C$ 0.53
-0.01 -1.85
39,700
113.40M
C$ 60.100M
US$ 3.42
-0.04 -1.16
106,785
17.54M
US$ 59.990M
US$ 2.28
0.06 2.47
73,036
26.08M
US$ 59.460M
US$ 1.02
-0.01 -0.97
96,978
56.57M
US$ 57.700M
US$ 1.45
0.06 4.32
124,121
39.39M
US$ 57.120M
US$ 0.13
0.0071 5.92
235,868
417.59M
US$ 53.030M
US$ 0.36
-0.04 -9.90
11.52M
145.47M
US$ 51.790M
US$ 0.85
-0.02 -2.41
138,079
60.93M
US$ 51.730M
US$ 1.70
-0.04 -2.30
10,674
30.25M
US$ 51.420M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 4.88
2.98 156.84
4,364
10.07M
US$ 49.140M
US$ 0.51
-0.0025 -0.49
167,709
95.97M
US$ 48.850M
C$ 0.38
0.02 4.17
32,500
119.77M
C$ 44.910M
US$ 1.59
0.005 0.32
49,615
26.67M
US$ 42.270M
C$ 0.17
0.005 3.03
7,611
247.78M
C$ 42.120M
C$ 0.41
-0.02 -3.53
10,000
93.38M
C$ 38.290M
US$ 6.85
-0.27 -3.79
16,226
5.25M
US$ 35.960M
US$ 4.23
-0.06 -1.40
54,743
8.27M
US$ 34.980M
US$ 1.67
0.07 4.06
17,546
20.24M
US$ 33.700M
US$ 0.83
-0.02 -1.88
117,458
40.14M
US$ 33.480M
US$ 0.58
-0.01 -2.03
417,387
57.89M
US$ 33.460M
US$ 5.02
0.10 2.03
113,156
6.55M
US$ 32.880M
C$ 0.28
-0.01 -3.45
16,000
113.10M
C$ 31.670M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.56
-0.02 -3.50
2.02M
55.19M
US$ 30.910M
US$ 1.37
-0.01 -0.72
277,000
20.75M
US$ 28.430M
US$ 0.72
0.03 4.04
143,440
38.39M
US$ 27.560M
US$ 3.23
0.13 4.19
22,449
8.53M
US$ 27.550M
US$ 2.59
0.33 14.60
69,893
10.54M
US$ 27.300M
C$ 0.27
0.00 0.00
0
90.89M
C$ 24.540M
US$ 1.06
0.05 4.95
105,749
22.90M
US$ 24.270M
C$ 0.31
0.00 0.00
0
77.42M
C$ 23.610M
C$ 0.08
0.005 6.67
80,000
270.17M
C$ 21.610M
US$ 0.74
-0.04 -4.66
81,373
27.52M
US$ 20.360M
US$ 0.64
0.01 2.17
65,788
29.94M
US$ 19.160M
C$ 0.32
-0.005 -1.54
9,000
59.60M
C$ 19.070M
US$ 0.62
0.01 2.41
183,632
30.84M
US$ 19.000M
C$ 0.12
-0.005 -4.17
94,588
159.67M
C$ 18.360M
US$ 0.32
0.00 0.00
0
52.24M
US$ 16.610M
US$ 4.42
0.07 1.61
14,234
3.73M
US$ 16.490M
US$ 0.99
-0.03 -2.94
79,230
16.64M
US$ 16.470M
US$ 1.23
0.03 2.50
59,028
13.30M
US$ 16.360M
US$ 2.22
-0.05 -2.20
26,469
7.26M
US$ 16.120M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 0.76
0.05 7.04
17,100
20.63M
US$ 15.680M
US$ 2.23
0.01 0.45
34,642
6.79M
US$ 15.140M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 9.75
-0.15 -1.52
9,120
1.48M
US$ 14.430M
US$ 0.33
0.0038 1.16
488,067
43.62M
US$ 14.390M
C$ 0.07
0.00 0.00
0
217.73M
C$ 14.150M
US$ 0.19
0.0061 3.32
414,991
72.19M
US$ 13.720M
US$ 1.26
0.07 5.88
189,127
10.63M
US$ 13.390M
US$ 0.38
0.01 2.97
55,219
31.90M
US$ 12.150M
US$ 2.05
-0.03 -1.44
132,664
5.89M
US$ 12.070M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.530M
US$ 0.46
0.05 11.00
50
24.39M
US$ 11.220M
US$ 0.50
0.002 0.40
160,029
22.45M
US$ 11.200M
US$ 2.47
-0.03 -1.20
4,547
4.17M
US$ 10.300M
US$ 0.69
-0.01 -1.43
1.05M
14.59M
US$ 10.050M
C$ 0.10
0.005 5.56
40,920
100.02M
C$ 9.500M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 3.94
0.13 3.41
80,916
2.05M
US$ 8.080M
US$ 2.95
0.12 4.24
90,847
2.71M
US$ 7.990M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 0.24
-0.01 -5.49
1.03M
31.93M
US$ 7.700M
US$ 1.28
-0.02 -1.54
192,174
6.00M
US$ 7.680M
US$ 0.10
0.00 0.00
0
73.90M
US$ 7.390M
US$ 0.65
0.02 3.14
227,544
11.07M
US$ 7.200M
C$ 0.02
-0.005 -25.00
194,971
451.63M
C$ 6.770M
US$ 0.97
-0.12 -11.01
2.81M
6.67M
US$ 6.470M
US$ 1.29
0.04 2.79
84,688
4.81M
US$ 6.200M
US$ 0.28
0.03 10.54
1.81M
22.00M
US$ 6.140M
US$ 0.40
0.03 9.02
108,125
13.96M
US$ 5.570M
C$ 0.11
0.00 0.00
0
48.23M
C$ 5.060M
C$ 0.05
0.00 0.00
7,000
101.29M
C$ 5.060M
US$ 0.85
-0.04 -3.98
49,818
5.85M
US$ 4.950M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 2.13
0.04 1.87
115,483
2.22M
US$ 4.730M
US$ 0.28
-0.008 -2.83
1.39M
15.58M
US$ 4.280M
US$ 0.62
-2.49 -80.06
1.79M
6.63M
US$ 4.110M
US$ 1.08
-0.10 -8.47
782,753
3.75M
US$ 4.050M
US$ 0.92
0.02 1.89
58,322
4.37M
US$ 4.010M
US$ 3.87
-0.04 -0.90
7,377
980,321
US$ 3.790M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 0.31
0.00 0.00
0
11.88M
US$ 3.650M
US$ 4.94
-0.18 -3.52
62,382
729,980
US$ 3.610M
US$ 0.17
0.06 52.21
10,962
21.04M
US$ 3.470M
US$ 1.10
-0.03 -2.65
201,440
3.14M
US$ 3.450M
US$ 1.84
0.04 2.22
23,083
1.77M
US$ 3.260M
US$ 1.50
0.00 0.00
0
1.82M
US$ 2.730M
US$ 0.25
0.00 0.00
0
10.59M
US$ 2.650M
US$ 0.84
-0.07 -7.84
115,290
2.46M
US$ 2.070M
US$ 0.21
-0.09 -30.46
1.44M
8.00M
US$ 1.680M
US$ 3.13
0.04 1.29
20,866
536,908
US$ 1.680M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.01
0.00 0.00
0
96.71M
US$ 1.350M
US$ 1.14
-0.005 -0.44
5,420
962,637
US$ 1.100M
US$ 0.20
0.00 0.00
0
5.24M
US$ 1.060M
US$ 1.84
0.00 0.00
26,442
552,854
US$ 1.020M
US$ 0.03
0.00 0.00
0
25.04M
US$ 851K
US$ 1.52
0.00 0.00
0
418,049
US$ 635K
US$ 0.08
0.00 0.00
0
7.26M
US$ 588K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.005
-0.09 -94.44
25
29.91M
US$ 150K
US$ 0.06
0.00 0.00
0
1.78M
US$ 109K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
0.00 0.00
0
6.39M
US$ -
US$ 0.00
0.00 0.00
0
855.04M
US$ -
C$ 0.40
0.00 0.00
46,500
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance... Read more


Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis. / May 22, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast... Read more


Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions MARLBOROUGH, Mass. / May 22, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®)... Read more


Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to feature largest study evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection in colon cancer using Guardant Reveal PALO ALTO, Calif. / May 22, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today... Read more


Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30... Read more


QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN’s global reach and automation expertise with ID Solutions’ assay development for research purposes and manufacturing strengths VENLO, Netherlands / May 22, 2025 / Business Wire / QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing... Read more


Inotiv to Present at Jefferies Global Healthcare Conference 2025

WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation... Read more


CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world... Read more


PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centers MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access... Read more


Ocumetics Technology Clinical Study Protocol Submission and Site Initiation on Schedule for Summer 2025

Calgary, Alberta – TheNewswire - May 22, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the submission of its first-in-human (FIH) clinical study protocol for IRB approval.  This development represents a critical step in the advancement of the Ocumetics Lens toward clinical trials planned for summer 2025, designed to assess safety,... Read more


Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing

INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually With over 450 active accounts across 24 countries, INBS continues to meet growing global demand for reliable, on-site drug testing solutions across the workplace, treatment, and justice sectors NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq:... Read more


Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes Precision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms... Read more


Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / May 22, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector,... Read more


Nano-X Imaging Announces First Quarter 2025 Financial Results and Provides Business Updates

Management to host conference call and webcast on Thursday, May 22, 2025 at 8:30 AM ET PETACH TIKVA, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2025, and provided a business update. Recent Highlights: Generated $2.8 million in revenue in the first quarter of 2025, compared to $2.6 million... Read more


Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the... Read more


Repligen to Present at William Blair Growth Conference

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will... Read more


Edwards Lifesciences: Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

PARIS / May 22, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare... Read more


WORK Medical Technology Announces Closing of Registered Offering

Hangzhou, China, May 22, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced the closing of a registered offering (the “Offering”) of 10,000,000 ordinary units (the “Ordinary Units”) at an offering price of $0.50 per Ordinary Unit. Each... Read more


Aurora Spine Announces Record First Quarter Financial Results

Company to host conference call Today, Thursday, May 22nd at 11am ET/8am PT  CARLSBAD, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for first quarter ended March 31, 2025. All figures are in U.S. dollars. Financial and Business Highlights FDA... Read more


GRAIL to Present at Jefferies Global Healthcare Conference 2025

MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available... Read more


Varex Imaging to Present at the Jefferies Global Healthcare Conference

SALT LAKE CITY / May 21, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the Jefferies Global Healthcare Conference in New York. Management will be presenting on Wednesday, June 4, 2025 at 8:10am ET. The webcast can be accessed here or on Varex’s website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components,... Read more


Sharps Technology to Present at the Aegis Capital Corp. 2025 Virtual Conference on May 22nd

Presentation to be webcast at 1:00 p.m. ET NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, is scheduled to present at the Aegis Capital Corp. 2025 Virtual Conference on May 22, 2025 at 1:00 p.m. ET.... Read more


MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy

MISSISSAUGA, Ontario / May 21, 2025 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed Biomedical, a MedX commercial partner in Italy, and Medispa, a leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. This new partnership will facilitate the deployment... Read more


Tempus AI to Present at the William Blair 45th Annual Growth Stock Conference

CHICAGO / May 21, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company... Read more


Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif. / May 21, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists... Read more


Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light... Read more


Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

VAUGHAN, Ontario / May 21, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye irritations. “Consumers often say how amazed... Read more


Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’... Read more


Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic Q4 GAAP diluted... Read more


Becton Dickinson: Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which includes BD (Becton, Dickinson and... Read more


Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new standalone company... Read more


Senseonics Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement

Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten... Read more


CONMED Appoints LaVerne Council as Chair of the Board of Directors

LARGO, Fla. / May 21, 2025 / Business Wire / CONMED Corporation (NYSE: CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. “LaVerne’s extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role... Read more


ReShape Lifesciences Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent Highlights May 2025: Effected... Read more


Penumbra to Present at Upcoming Investor Conferences

ALAMEDA, Calif., May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: William Blair 45th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 3:00pm ET/12:00pm PT Event: Jefferies Global Healthcare Conference Date: Wednesday,... Read more


TransMedics to Present at Upcoming June Investor Conferences

ANDOVER, Mass., May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 5:00... Read more


Tactile Medical to Present at Upcoming Investor Conferences in June

MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will be participating in two upcoming investor conferences. Tactile Medical is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 3:20 p.m. CST and at the... Read more


Warby Parker Partners with Google To Develop Intelligent Eyewear

AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership NEW YORK / May 20, 2025 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended... Read more


HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. Event Details: Date: Wednesday,... Read more


BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring an artificial intelligence (AI) approach using... Read more


Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers PALO ALTO, Calif. / May 20, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test,... Read more


Merit Medical Systems Acquires Biolife Delaware

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates... Read more


Helius Medical Technologies to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

Shepherd Center’s Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic... Read more


INVO Fertility Announces First Quarter 2025 Financial Results

Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and te... Read more


Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing... Read more


Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025.... Read more


VolitionRx Announces Successful Detection of Nucleosomes in Cats

Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been... Read more


Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume workforce drug test for Barcaldine Regional... Read more


Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease and therapeutic drug monitoring WALTHAM, Mass. / May 19, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked... Read more


STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (May 2025: CPT® Editorial Summary of Panel Actions | AMA) has accepted revision to CPT codes 96920-96922, expanding reimbursement... Read more